Analysts are modeling that earnings per share and revenue will fall year-over-year.
Wall Street is expecting the Paris-based pharmaceutical company to report earnings of 72 cents per share on revenue of $10 billion.
During the same period last year, Sanofi earned $1.47 per share on revenue of $10.4 billion.
Last night, the company announced that it received FDA approval for its type 2 diabetes treatment Adlyxin.
Separately, TheStreet Ratings Team has a "Hold" rating with a score of C+ on the stock.
The primary factors that have impacted the rating are mixed. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth and expanding profit margins.
But the team also finds that the stock has had a generally disappointing performance in the past year.
Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
You can view the full analysis from the report here: SNY